Judge's ruling gives 'wide latitude' to plaintiffs' in lawsuits against Omniscan imaging drug

NewsGuard 100/100 Score
ProPublica: In a key ruling, "a federal judge has given plaintiffs' lawyers wide latitude to present evidence and expert testimony that GE's Omniscan imaging drug caused a crippling disease in MRI patients." The judge issued his ruling from Cleveland as the first cases against GE get ready for a move to trial. Federal District Judge Dan Polster "criticized GE Healthcare's lawyers and witnesses for relying on misleading and flawed presentations as they sought to quash the plaintiffs' theories. ... Omniscan has been linked to a rare but often crippling disease, called nephrogenic systemic fibrosis, or NSF, in patients with kidney problems. Lawyers for NSF victims claim the company failed to adequately warn doctors and patients about the dangers." Omniscan is named in 400 of 500 similar cases that Polster is managing. ProPublica reports that the ruling, made public late Tuesday, "is procedural and sets parameters on expert testimony each side may present at upcoming trials" (Gerth, 5/5).


Kaiser Health NewsThis article was reprinted from khn.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New machine learning model achieves breakthrough in heart disease prediction with over 95% accuracy